OTLC (Oncotelic Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


What is Oncotelic Therapeutics EBITDA Margin %?

Oncotelic Therapeutics OTLC -15.51% EBITDA Margin % is 0.00% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Oncotelic Therapeutics ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oncotelic Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-1.94 Mil. Oncotelic Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Oncotelic Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Oncotelic Therapeutics  (OTCPK:OTLC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Oncotelic Therapeutics EBITDA Margin % Related Terms

Oncotelic Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Oncotelic Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncotelic Therapeutics EBITDA Margin % Chart

Oncotelic Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -10,230.00 0.00 0.00

Oncotelic Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OTLC vs ALLR, MRKR, SKYE: EBITDA Margin % Comparison

For the Biotechnology subindustry, Oncotelic Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncotelic Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Oncotelic Therapeutics's EBITDA Margin % falls into.


Oncotelic Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Oncotelic Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=361.46/0
= %

Oncotelic Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.943/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Oncotelic Therapeutics (OTLC) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncotelic Therapeutics and its competitors. According to the industry distribution chart, Oncotelic Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Oncotelic Therapeutics' EBITDA Margin % too high?
Oncotelic Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Oncotelic Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Oncotelic Therapeutics' EBITDA Margin % compare to ALLR and MRKR?
According to the Biotechnology industry distribution chart, Oncotelic Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Oncotelic Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncotelic Therapeutics and its competitors. Oncotelic Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncotelic Therapeutics Business Description

Address 29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.